Innate Pharma: a new strategy for growth

(CercleFinance.com) - Innate Pharma presents a transformation strategy to accelerate its growth, a strategy 'focused on the early clinical development of proprietary molecules with monotherapy potential'.


Within this framework, it plans to drive innovation through its ANKET platform, accelerate the development of differentiated antibody-drug conjugates, and advance assets currently in late-stage development through partnerships.

This roadmap reflects our ongoing commitment to advancing science, strengthening partnerships and maximizing value for patients and shareholders", comments Chairman Jonathan Dickinson.

Copyright (c) 2025 CercleFinance.com. All rights reserved.